<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11649">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01970306</url>
  </required_header>
  <id_info>
    <org_study_id>13-178</org_study_id>
    <nct_id>NCT01970306</nct_id>
  </id_info>
  <brief_title>Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material</brief_title>
  <official_title>A Prospective Phase II Trial to Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan-Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ACell Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan-Kettering Cancer Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if implanting MatriStem will lower the risk of one of
      the more common complications after stomach or esophagus surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>rates of anastomotic leak.</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Anastomotic leak will be assessed by clinical observation and one postoperative contrast study (thin-barium of Gastrografin swallow)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stricture formation clinically and by determination of dysphagia score</measure>
    <time_frame>90 days postoperatively</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be evaluated in the outpatient clinic and will be assigned a dysphagia score from 0-4 by the RSA. Patients reporting symptoms consistent with stricture will be evaluated with radiographic contrast swallow study or endoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cost metrics</measure>
    <time_frame>postoperatively (+/- 14 days)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Data for cost metrics will be collected postoperatively through POD90 (+/- 14 days). These include metrics such as Length of Stay, Readmission, Complications, Reoperation and Total Hospital Bill.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Surgical intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MatriStem PSM</intervention_name>
    <description>All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.</description>
    <arm_group_label>Surgical intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient 18 years of age or older

          -  Pathologically confirmed Gastric, Gastroesophageal Junction (GEJ) or Esophageal,
             adenocarcinoma at MSKCC (biopsy may be performed at other institutions but slides
             must be confirmed at MSKCC, as is routine care at our institution)

          -  Patient undergoing any resection requiring an anastomosis to the esophagus for
             curative intent. Including but not limited to esophagectomy or total gastrectomy.

          -  Subject is willing to provide written informed consent

          -  Subject is willing and able to comply with the follow-up regimen

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Intraoperative evidence of metastatic or locally-unresectable disease

          -  Patients with known sensitivity or allergy to porcine materials.

          -  Patients undergoing any resection requiring an anastomosis to the esophagus for
             palliative intent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian Strong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan-Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivian Strong, MD</last_name>
    <phone>212-639-5056</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nabil P. Rizk, MD</last_name>
    <phone>212-639-8357</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Strong, MD</last_name>
      <phone>212-639-5056</phone>
    </contact>
    <contact_backup>
      <last_name>Nabil P. Rizk, MD</last_name>
      <phone>212-639-8357</phone>
    </contact_backup>
    <investigator>
      <last_name>Vivian Strong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivian Strong, MD</last_name>
      <phone>212-639-5056</phone>
    </contact>
    <investigator>
      <last_name>Vivian Strong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>October 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal Reinforcement</keyword>
  <keyword>ACell MatriStem</keyword>
  <keyword>13-178</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
